Jason Fair

Family man with two young boys. Expert #videomarketing 🎥#HCPmarketer #HCPadvertising 🩺 Food/craft beer 🍺 vizsla 🐾 Triathlons 🏊🏼‍ 🚴🏻‍♀️ 🏃 & San Diego

[Jon Strum @RealTalkMS_jon]

https://t.co/zDt21gHovL: This week’s takeaway: MS wellness goes beyond symptom management. Oral health, research participation, and innovation all contribute to improving quality of life.
Listen to the latest #RealTalkMS episode today wherever you get your podcasts.
#MultipleSclerosis #MSResearch #MSAwareness #MSCommunity

[ASCO @ASCO]

Heading to #ASCO26? Make sure the Social Media Meetup is on your schedule! 🗓️

Join us for networking, photobooth fun, & great conversation on Friday, May 29, 3:45 to 5 PM in the Trainee & Early Career (TEC) Lounge.

This event is open to all registered professional attendees.

[DigiVidBio @DigiVidBio]

Making your lab look camera-ready without making it feel staged.

We show how we balance authenticity with clean, professional visuals through smart pre-production and on-set decisions.

Subscribe so you don’t miss it:
https://t.co/tIuwsLGcfd

#HealthcareMarketing

[DigiVidBio @DigiVidBio]

What drives the cost of a healthcare video?

The same video budget can lead to very different outcomes.

We broke it down in our latest Production Lab episode & companion blog.

🎥 https://t.co/EwJZQJqhIW

📖 https://t.co/wwNGXlXaaN

#HealthcareMarketing

[Natera @NateraGenetics]

We are incredibly proud to share that the FDA has approved Signatera™ CDx as a companion diagnostic for use with adjuvant atezolizumab (Tecentriq®) in muscle-invasive bladder cancer. This is the first FDA-approved molecular residual disease (MRD) companion diagnostic in history – a milestone to celebrate on many levels!

Today’s news speaks volumes to the transformation well underway in MRD-guided cancer care. Signatera has become a cornerstone of precision oncology, with extensive support from more than 185 peer-reviewed publications.

By detecting microscopic amounts of tumor DNA in the blood, Signatera can identify MRD earlier than standard tools, allowing physicians to intervene sooner and improve outcomes for patients. Just as importantly, Signatera can help identify patients who are MRD-negative and may be able to avoid unnecessary therapy and its associated toxicity. Altogether, this has a tremendous impact on the lives of patients and their loved ones.

This approval was supported by the landmark Phase III IMvigor011 study, published in The New England Journal of Medicine, which demonstrated the power of MRD-guided treatment decisions in bladder cancer. We’d like to thank our esteemed collaborators at @Genentech and @Roche, the principal investigators of IMvigor011, and our clinical trial participants for their contributions to this major milestone in cancer care.

Read the full press release here: https://t.co/922E459e0V

#PrecisionMedicine #Oncology #Natera

[DigiVidBio @DigiVidBio]

In Part 2 of The Honest Video Budget Episode, we unpack:

• why teams stay stuck in reactive production cycles
• how a long-term content approach creates more value across campaigns, channels, and future marketing needs

🔗https://t.co/EwJZQJqhIW

[DigiVidBio @DigiVidBio]

The Honest Video Budget Episode (Part 1) digs into how video can have a longer shelf life.

Watch the full episode or read the blog for more.

YouTube: https://t.co/Nihd85YbYf

Blog: https://t.co/wwNGXlXaaN

#HealthcareMarketing #VideoStrategy #ContentLibrary #MedTechMarketing

[Natera @NateraGenetics]

Congratulations to Sheetal Parmar, M.S., CGC, SVP, medical affairs, women’s health at Natera, who was recently named one of the Most Influential Women in Bay Area Business by @SFBusinessTimes!

Sheetal is a board-certified genetic counselor who, over the course of her nearly 25-year career, has advanced groundbreaking prenatal testing solutions, including our Panorama™ NIPT and Fetal Focus™ single-gene NIPT. She is also a dedicated mentor and champion of professional development for the next generation. We are grateful for her commitment and insight to help drive our mission forward.

Congratulations, Sheetal!

See the full list: https://t.co/xvOGd3dtFF

#Natera #SFBTwomen

[RSNA @RSNA]

Don't miss your chance to apply for the Derek Harwood-Nash International Fellowship!

This opportunity provides faculty members from international institutions the opportunity to study at a North American institution. During the fellowship, you will observe radiology procedures and participate in conferences specifically related to your area of study.

Submit your application by July 1: https://t.co/RDMvDT9Iuq

[Natera @NateraGenetics]

Yesterday we announced financial results for the 1st quarter of 2026. We delivered strong performance across all areas of focus, capping an exciting period of growth for Natera. The quarter included a number of important milestones, anchored by data generation, innovation, and a powerful commitment to our mission. Most importantly, we continue to remain confident in our ability to continue transforming care for our patients.

https://t.co/zWsW0jSaHu

[DigiVidBio @DigiVidBio]

If every video is a one-off, you’re leaving value on the table.

When everything is built for a single moment, you miss the chance to extend value across campaigns and channels.

We’re digging into how to change that in an upcoming episode on May 14th.

https://t.co/tIuwsLGcfd

[Natera @NateraGenetics]

See you at #ACOG2026! Stop by booth #541 to speak with our experts and explore how Natera continues to advance prenatal genetic care.

There's still time to register for our dinner presentation, An Inside Look: Landmark EXPAND data supporting Fetal Focus™ and Natera’s future product roadmap, here: https://t.co/o3nXaKHc8U

#Natera #ACOG @ACOG

[DigiVidBio @DigiVidBio]

Drowning in approvals, planning, and the push for “more content”?

Let a partner handle the rough cut—flag standout moments, prep clips, and leave you with quick approvals.

Fewer delays. Steadier output.

https://t.co/tIuwsLGcfd

#HealthcareMarketing #ContentOps #MedTech

[Natera @NateraGenetics]

Join our upcoming webinar, Advancing testicular cancer management with ctDNA: Clinical utility of Signatera™ for MRD detection and surveillance with @DrJohnSfakianos, @nabiladra, and Ashley Wray, DMSc, MPH, PA-C.

Register here: https://t.co/tmjsirCWht

Learn more about:

• Clinical performance of ctDNA vs conventional serum tumor markers (AFP, hCG) in germ cell tumors
• Association of ctDNA positivity with recurrence risk in MRD and surveillance settings
• Integration of ctDNA into post-orchiectomy and post-chemotherapy management decisions
• Case-based discussion illustrating real-world clinical application

[Natera @NateraGenetics]

Thank you everyone at #ISHLT2026 who attended our lung symposium, dd-cfDNA beyond rejection: Decoding molecular injury in lung transplantation. Our panel featured Jason Li, Transplant Fellow, Fatima Anjum, MD, MHA, Nirmal S. Sharma, MD, and Holly Keyt, MD.

#Natera @ISHLT

[Inform Diagnostics - A Fulgent Genetics Company @Inform_Dx]

Happy #LabWeek to our incredible InformDx lab team. Behind the scenes, they work around the clock to deliver fast, accurate results, never losing sight that there’s a person behind every sample being tested.

Thank you for all that you do! #pathology #Diagnostics #LabWeek2026

[DigiVidBio @DigiVidBio]

Good content doesn't just drive awareness.

It builds trust that keeps partners, HCPs, and collaborators coming back.

That starts with how you manage the process, not just what you produce.

New blog + episode 👇
📹 https://t.co/5moml9sSBd

📑 https://t.co/vDPzFWLkdE

[DigiVidBio @DigiVidBio]

The most delicate part of stakeholder management is protecting the integrity of the content while people see it from different angles.

This conversation gets into the real tension.

Watch the full episode on YouTube.

YouTube: https://t.co/5moml9sSBd

[Natera @NateraGenetics]

Dr. Lodhi shares how she can remain proactive for her potentially high risk transplant patients with routine use of the Prospera™ test. Learn more: https://t.co/pZAgHjYsOO
#Natera #Transplant

[Jon Strum @RealTalkMS_jon]

https://t.co/cGfW1gzp9W
At the end of 2025, Congress failed to renew enhanced premium tax credits for health insurance purchased through the ACA online marketplace. How did that decision affect Americans and their healthcare? The numbers are in. And we're sharing them. On RealTalk MS #MultipleSclerosis #MSActivist